Mario Cesar Torres-Chavez

Mario Cesar Torres-Chavez

Auto-generated profile, based on publicly available information

Mario Cesar Torres-Chavez

Facultad de Medicina Mexicali Universidad Autónoma de Baja California Mexicali Baja California México

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2024 in World Neurosurgery
Verified
Journal Article
Closed access
PPPavel S. Pichardo-Rojas
Pavel S. Pichardo-Rojas
LMLuis A. Marín-Castañeda
Luis A. Marín-Castañeda
FVFernando De Nigris Vasconcellos
Fernando De Nigris Vasconcellos
SFShadia I. Flores-López
Shadia I. Flores-López
ACAdrian Coria-Medrano
Adrian Coria-Medrano
LRLeonardo Rangel-Castilla
Leonardo Rangel-Castilla

17 July 2026 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
MTMario Cesar Torres-Chávez
Mario Cesar Torres-Chávez
JGJaretzy García-Manteca
Jaretzy García-Manteca
JSJacqueline A. Seiglie
Jacqueline A. Seiglie
OBOmar Yaxmehen Bello-Chavolla
Omar Yaxmehen Bello-Chavolla
NANeftali Eduardo Antonio-Villa
Neftali Eduardo Antonio-Villa
Type 2 diabetes (T2D) is a heterogeneous disease and a major public health concern in low- and middle-income countries (LMICs). To address this heterogeneity, several subgroup classification frameworks have been proposed. Among them, the most widely used is the data-driven classification proposed by Ahlqvist et al., which includes severe autoimmune diabetes (SAID), severe insulin-deficient diabetes (SIDD), severe insulin-resistant diabetes (SIRD), mild obesity-related diabetes (MOD), and mild age-related diabetes (MARD). However, reproducing this framework is limited by the need for specialized measurements of beta-cell function and insulin resistance, which are not routinely available in most clinical or epidemiological settings in LMICs. To overcome these barriers, we derived a classification algorithm to reproduce these diabetes subgroups. Here, we present a four-step roadmap in which this framework may help characterize T2D heterogeneity across Mexico, potentially guide pathophysiology-oriented treatment strategies, support public health monitoring, and enhance our understanding of T2D heterogeneity to improve diabetes care in our country.

21 August 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MTMario Cesar Torres-Chavez
Mario Cesar Torres-Chavez
NANeftali Eduardo Antonio-Villa
Neftali Eduardo Antonio-Villa
MGMauricio Gonzalez-Arias
Mauricio Gonzalez-Arias
DADiego Araiza-Garaygordobil
Diego Araiza-Garaygordobil
PMPablo Martinez-Amezcua
Pablo Martinez-Amezcua
Body mass index (BMI) alone may underestimate clinically relevant obesity because it does not capture central fat distribution. We compared obesity prevalence in Mexico using BMI-only criteria, adiposity-confirmed criteria, and the clinical obesity definition proposed by the Lancet Diabetes and Endocrinology Commission. We conducted a population-based, cross-sectional study of 13,160 adults aged 18 years or older who participated in the 2018-2019 Mexican National Health and Nutrition Survey (ENSANUT). Obesity prevalence was estimated through survey-weighted analyses that accounted for the complex sampling design. The weighted prevalence of obesity based on BMI was 34.5% (95% CI, 33.1-35.9), while 30.9% (95% CI, 29.6-32.2) met criteria for clinical obesity. One quarter of individuals with clinical obesity had a BMI under 30 kg/m 2 , a phenotype more common among older adults. Half of adults with a BMI under 30 kg/m 2 showed elevated central adiposity. BMI alone underestimates clinically relevant obesity in Mexican adults. Adding waist-based measurements could improve the identification of individuals with excess fat and metabolic risk, both in clinical settings and population monitoring.

31 October 2026 in Clinical Cardiology
Verified
Journal Article
Open access
EEErmilo Echeverria‐Ortegon
Ermilo Echeverria‐Ortegon
MTMario César Torres‐Chávez
Mario César Torres‐Chávez
ATAlfredo Pérez‐Tagle Tejeda
Alfredo Pérez‐Tagle Tejeda
POPaulina Caballero Osorno
Paulina Caballero Osorno
JPJuan Pastor‐Cervantes
Juan Pastor‐Cervantes
HLHugo Laviada‐Molina
Hugo Laviada‐Molina
Background: Patients with type 2 diabetes mellitus (T2DM) who experience acute coronary syndromes (ACS) remain at high risk for recurrent ischemic events despite secondary prevention. Lipoprotein(a) [Lp(a)] contributes to residual cardiovascular risk, but its prognostic impact on recurrent myocardial infarction (MI) and repeat revascularization in diabetic patients after ACS or percutaneous coronary intervention (PCI) remains unclear. Hypothesis: We hypothesized that elevated Lp(a) is associated with increased risk of recurrent MI and repeat coronary revascularization in patients with diabetes after ACS or PCI. Methods: We conducted a PRISMA‐guided systematic review and meta‐analysis. PubMed, EBSCOhost, and Cochrane Library were searched for studies evaluating Lp(a) and recurrent cardiovascular outcomes in patients with diabetes after ACS or PCI. Observational studies reporting hazard ratios (HRs) with 95% confidence intervals (CIs) were included. Pooled HRs were calculated using random‐effects models. Results: Seven studies comprising 7887 patients with diabetes and prior ACS or PCI were included. Elevated Lp(a) was associated with increased risk of recurrent MI (pooled HR 2.17, 95% CI 1.02–4.62; I 2 = 75%) but not repeat coronary revascularization (pooled HR 1.68, 95% CI 0.79–3.57; I 2 = 78%). Conclusions: Elevated Lp(a) was associated with increased risk of recurrent MI in patients with diabetes after ACS or PCI. Findings should be interpreted considering the observational study designs, substantial heterogeneity, and limited evidence for repeat revascularization. These findings support Lp(a) as a contributor to residual cardiovascular risk and its potential role in post‐ACS risk stratification. Trial Registration: This study was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO; registration number CRD420261296821).